Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Berkley Renewables Inc.

Market Cap 4L 3L 3L 3L 5L 3.46Cr 5L 34.25L 13.35L 1.69Cr 13.68L 13.38L 5.84Cr P/E Ratio 2016
4.22x
P/E Ratio 2017 -1.16x
Enterprise Value 51.26L 44.27L 40.79L 38.19L 71.56L 49Cr 72.67L 4.82Cr 1.88Cr 24Cr 1.92Cr 1.88Cr 82Cr EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
10 years 0.02
Extreme 0.015
0.15
Manager TitleAgeSince
Chief Executive Officer 63 20/06/2002
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 17/08/2006
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-.--% 5L
+0.81%-6.10%+33.26%+120.92% 16TCr
+1.40%-0.14%+20.65%+13.12% 14TCr
-0.19%-0.56%+38.13%+69.79% 9.45TCr
+0.09%-0.82%+9.08%+21.23% 7.28TCr
+1.93%-0.69%+21.72%-3.79% 5.62TCr
+0.28%-0.25%+24.03%+47.72% 5.4TCr
-0.80%+0.15%+95.78%+74.72% 5.29TCr
+1.57%+2.33%+29.05%-10.08% 5.23TCr
-0.92%+1.04%+23.88%-8.87% 4.19TCr
Average +0.42%-0.98%+29.56%+32.48% 7.23TCr
Weighted average by Cap. +0.61%-1.70%+31.12%+47.47%

Financials

2016 2017
Net sales 10.34L 9L 8L 8L 14.44L 9.83Cr 14.66L 97.18L 37.89L 4.78Cr 38.81L 37.98L 17Cr 17.25L 14.9L 13.73L 12.85L 24.08L 16Cr 24.45L 1.62Cr 63.2L 7.98Cr 64.73L 63.35L 28Cr
Net income 2L 1L 1L 1L 2L 1.64Cr 2L 16.23L 6L 79.9L 6L 6L 2.77Cr -6L -5L -5L -5L -9L -5.99Cr -9L -59.25L -23.1L -2.92Cr -23.66L -23.16L -10Cr
Net Debt 29.17L 25.19L 23.22L 21.73L 40.73L 28Cr 41.36L 2.74Cr 1.07Cr 13Cr 1.09Cr 1.07Cr 47Cr 47.61L 41.12L 37.89L 35.47L 66.47L 45Cr 67.5L 4.47Cr 1.74Cr 22Cr 1.79Cr 1.75Cr 76Cr
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!